Background. Primary hyperparathyroidism is an endocrine disease resulting from a primary pathology of the parathyroid gland, characterized by increased secretion of parathyroid hormone and increased blood calcium levels. Among the endocrine diseases, primary hyperparathyroidism is the third most common after diabetes mellitus and thyroid disease. Without timely diagnosis, primary hyperparathyroidism causes systemic damage to internal organs: renal impairment, nephrolithiasis, esophageal affection, cardiovascular and nervous system and affects bones. The aim of the work was to present a clinical case of a patient with primary hyperparathyroidism and to analyze the stages of its diagnosis and treatment. Material and methods. We reviewed the relevant literature and analyzed the patient’s medical records. Results and Discussion. The patient had a complicated course of primary hyperparathyroidism of bone and visceral form. Despite of the slow progression and availability of screening methods, hyperparathyroidism was detected at the stage of complications. The efficacy of the therapy has been assessed. The underlying reasons that made it difficult to diagnose PHPT at an early stage, before the development of serious complications of internal organs were investigated. Conclusions: It can be assumed that our clinical case will increase the awareness of physicians, especially therapists, about the primary manifestations of this pathology and the challenges of its detecting and avoiding diagnostic errors.

Introduction. Primary hyperparathyroidism is an endocrine disease resulting from a primary pathology of the parathyroid gland, characterized by increased secretion of parathyroid hormone and increased blood calcium levels. Among the endocrine diseases, primary hyperparathyroidism is the third most common after diabetes mellitus and thyroid disease. In Russia, according to epidemiological studies, primary hyperparathyroidism is found in 1% of the population, women suffer 2-3 times more often than men do, and the average age of diagnosis is 54-59 years. In the absence of a timely diagnosis, primary hyperparathyroidism causes systemic damage to internal organs: renal impairment, nephrolithiasis, esophageal affection, cardiovascular and nervous system involvement, and it leads to a violation of bone tissue integrity. The aim is to demonstrate a clinical case of a patient with primary hyperparathyroidism and to analyze the stages of diagnosis of the disease and treatment. Material and methods. The review of medical literature on the problem of diagnostics and treatment of primary hyperparathyroidism was performed, as well as an analysis of the patient’s medical documentation with this pathology. Results and discussion. A variant of complicated course of primary hyperparathyroidism of bone and visceral form is considered. About 15 years passed from the moment of appearance of the first symptoms of the disease to the development of complications of renal and bone system. Despite the slow development of the disease and availability of screening methods, hyperparathyroidism was detected at the stage of complications. This article provides a detailed analysis of the primary hyperparathyroidism history, as well as analyzes the possibilities of diagnosis, treatment and prevention of this pathology. The efficacy of the therapy has been assessed, and ways of correction have been outlined. The analysis of the reasons that made it difficult to diagnose this pathology at an early stage, before the development of serious complications of internal organs, has been carried out. Conclusions: It can be assumed that the presented clinical case will increase the awareness of physicians, especially therapists, about the primary manifestations of this pathology and the peculiarities of its detection and routing the patient, which will allow avoiding many diagnostic errors.

The purpose of this article is to analyze the range of medicines that are used in the treatment of skin diseases. This topic is currently relevant, since the analysis of retail sales allows you to assess the financial condition of a pharmacy organization, identify unclaimed drugs, develop measures to stimulate sales, as well as study customer demand and develop a strategy for product movement. Accordingly, conducting a study of the main indicators of the assortment of this group of drugs will make it possible to expand their representation on the shelves of pharmacies, as well as to study the demand for them from potential consumers. During the analysis, the following data were obtained. The range under study was represented in the pharmacy by 22 items. The analysis of dosage forms of medicines intended for the treatment of skin diseases showed that liquid dosage forms accounted for 22.73%; solid dosage forms - 4.55%; soft dosage forms – 59.08%; gaseous dosage forms -13.64%. When analyzing the drugs, it was revealed that the largest number in the assortment is synthetic drugs - 68.18%; the share of phytopreparations was 31.82%. Analysis of the producing countries showed that most of the drugs presented to the pharmacy by domestic producers (54,53%), in the second place drugs manufactured in India -18,17%; third place was shared by countries: Poland, Croatia, Belgium, Germany, Czech Republic, USA -4,55%. The analysis of price categories of pharmaceuticals for the treatment of skin diseases revealed that in the price category from 100 to 200 RUB presents 22,73% of drugs; in the category from 200 to 300 rubles-49,89%; from 300 to 400 rubles from 33.73%; from 400 to 700 rubles - on 4,55%.